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a b s t r a c t
Metastatic tumours to the pituitary gland are rare. The most frequent are metastases from
breast and lung. We describe three patients with metastatic tumours: (I) a 54-year-old
patient with metastatic renal clear-cell carcinoma and consequent disturbances in visual
acuity, cranial nerve paresis and panhypopituitarism, (II) a 60-year-old patient with a diffuse
large B-cell lymphoma with panhypopituitarism and diabetes insipidus and (III) a 57-year-
old patient with metastasis of breast cancer and panhypopituitarism, visual impairment
and cranial nerve paresis. A transnasal endoscopic biopsy and resection of the tumour was
performed in all patients, followed by the oncological treatment. Despite the rarity of the
disease, it is important to suspect a metastatic pituitary tumour especially in the case of
diabetes insipidus, ophthalmoplegia, rapid course of the disease and headaches. In 20–30%
of patients, a metastasis to the pituitary is the ﬁrst manifestation of a tumour of unknown
origin. Surgical and adjuvant therapy may improve the quality of life. The survival is not
affected, however, and the prognosis of the disease is usually poor.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Metastatic pituitary tumours are rare complications of
malignancy, representing only 1% of surgical tumours of
pituitary gland. They are usually encountered in elderly
patients with disseminated malignant disease [1,2]. The most
frequent are metastases of breast and lung cancer. The* Corresponding author at: Department of Neurosurgery, University M
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the last decade due to the improved diagnostics, advances in
oncological treatment and longer survival of patients with
malignant tumours [3]. In 20–30%, the metastatic tumour to
pituitary may signify the ﬁrst manifestation of a malignant
tumour of unknown origin and therefore requires a compre-
hensive diagnostic workup. There are, however, no clear
criteria to distinguish between a pituitary adenoma and aedical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia.
p. z o.o. All rights reserved.
Fig. 2 – MRI of the head after the surgery with postoperative
changes and without residual tumour.
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with metastatic tumours of various aetiologies to the pituitary
gland. The biopsies and resections of the tumours were
performed through a transnasal endoscopic approach.
2. Presentation of patients
2.1. The ﬁrst patient
In a 54-year-old lady, a nephrectomy due to a renal cell
carcinoma was performed six years ago. After a period of
stable clinical condition, the disease has eventually relapsed
with fatigue, abdominal pain, general wasting and weight loss.
The computer tomography (CT) of the chest and abdomen
showed metastases in the pancreas and lungs. Three weeks
before admission to the neurosurgical department, the patient
has inadvertently lost 8 kg and started to experience a burning
pain in the eyes and extensive lacrimation, followed by the
right eyelid ptosis, worsening of visual acuity with double
vision and headache. Imaging of the head showed a tumour in
the pituitary gland of 2.5 cm in diameter with the destruction
of surrounding bone and tumour invasion into the right
parasellar space (Fig. 1).
In clinical examination, severe amblyopia was evident,
more pronounced on the right eye (the visual acuity was 0.2
with right-sided visual ﬁeld defect only on the right eye),
paresis of the right oculomotor and abducent nerve and
panhypopituitarism. The hormone proﬁle was characteristic
for panhypopituitarism. The levels of blood glucose and serum
electrolytes were still within the normal range. The ﬂuid
balance was not affected. The patient has received hormoneFig. 1 – The first patient before surgery. MRI reveals a
tumour of the pituitary gland (histologically metastasis of
renal cell carcinoma), destructing the surrounding bone
and invading to the right parasellar space (arrow).replacement therapy and as a result of progressive deteriora-
tion of vision, a decompressive operation was indicated.
Through a transnasal endoscopic approach, the tumour was
extensively reduced. Histology conﬁrmed the metastasis of
renal clear-cell carcinoma. Postoperatively, the visual acuity
improved bilaterally, while the paresis of ocular nerves and
panhypopituitarism persisted. The pain in the eyes as well as
the excessive lacrimation gradually subsided. After the
operation and recovery, radio- and chemotherapy followed.
On the control imaging of the head after surgery, there was no
tumour residue visible (Fig. 2). The same clinical status
persisted also three months after surgery during the follow-
up, when no signs of relapse in the pituitary were documented.
The survival time of the patient was eight months.
2.2. The second patient
One month before the admission, a 60-year-old man started to
experience fatigue, weight loss, night sweats, pain in the mid
abdomen and below the right costal arch, often followed by
nausea, vomiting and dizziness. A CT scan of the abdomen
showed a lesion in the adrenal glands. Extended diagnostics
revealed cystic lesions in the liver, calciﬁed oesophageal
lymph nodes and leukopenia. A CT-guided puncture of the
right adrenal gland was performed and the histological
examination conﬁrmed a diffuse large B-cell lymphoma.
Laboratory tests pointed to the hypopituitarism with impaired
function of the adrenal, thyroid and gonad axis. Magnetic
resonance imaging (MRI) of the head showed a tumour of the
pituitary gland, spreading to the suprasellar space and
compressing the optic chiasm (Fig. 3). The neurological status,
including vision, was normal. Through a transnasal endo-
scopic approach, a biopsy of the intrasellar tumour was done.
The postoperative course was good. Histology conﬁrmed a
Fig. 3 – MRI of the second patient before surgery showing a
pituitary tumour (histologically B-cell lymphoma)
spreading suprasellary and compressing on the optic
chiasm (arrow).
Fig. 4 – MRI after the procedure shows the reduction of
tumour (regression of the lymphoma in the central nervous
system).
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followed. A control MRI of the head two months and then
three years after surgery showed a tumour reduction and a
regression of lymphoma in the central nervous system (Fig. 4).
Four years after the diagnosis, the disease is still in remission.
Due to panhypopituitarism, the patient needs hormone
replacement therapy with hydrocortisone, thyroxin and
testosterone and due to diabetes insipidus treatment with
desmopressin is necessary.
2.3. The third patient
A 57-year-old lady was treated for breast carcinoma with
metastases in the bones and lungs. She had been diagnosed
with panhypopituitarism six months before the admission.
The MRI of the head showed a small tumour in the pituitary
gland and follow-up was recommended. Initially, the patient
experienced headaches, followed by double vision when
looking down due to the paresis of the right trochlear nerve
and somewhat less also of the left one. A control MRI showed
an increase of the tumour size with extension to the
suprasellar space and towards both cavernous sinuses
(Fig. 5). In few months, the tumour had grown rapidly. The
vision deteriorated, as well as the bulbomotorics. Through a
transnasal endoscopic approach, a tumour reduction in the
sellar and suprasellar space was carried out. The postoperative
course after endoscopic tumour reduction in the sellar and
suprasellar space was uneventful. However, cerebrospinal
ﬂuid (CSF) leakage was seen after a few days and required a
revision. In addition to the nasal septum vascularized ﬂap
(Hadad ﬂap) that was used during the initial skull base closure,
focal fat grafts and collagen sponge were ﬁtted into the
osseous cranial base gaps, covering them completely. The
ﬁbrin glue was sprayed on top, sealing the defect watertightly.Fig. 5 – The third patient before surgery. MRI shows a
pituitary tumour (histologically metastasis of breast
carcinoma), which expands suprasellary and into the
cavernous sine (arrow).
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relieving the CSF pressure. The leakage stopped and the
postoperative course was without incidents. The histological
examination conﬁrmed metastasis of a glandular breast
carcinoma, positive for hormone receptors. Oncological
treatment, which included radio- and chemotherapy, followed
two weeks after the revision surgery. One year after the
surgery, the patient is still being followed-up and the disease
course is stable.
3. Discussion
Pituitary metastases are rare and can be found in 1% of
resected hypophyseal tumours [1]. Among intracranial metas-
tases, they represent from 0.8% to 1.9% of all cancer biopsies
[2]. According to some studies, the incidence is between 0.14%
and 28% and is increasing in recent decades due to better
diagnosis and treatment of the underlying disease and
prolonged survival rate of these patients [2,3]. There are not
many reports about metastatic cancers into hypophysis;
generally, only descriptions of individual cases and small
series of patients with pituitary metastases may be found.
Taking into account the biopsies involving the pituitary gland
and the surrounding area of the sella, the percentage of
metastases in this area increases up to 27% [1]. The most
common metastatic tumours to the pituitary are breast and
lung cancer in 37.2% and 24.2%, respectively [2]. In female
population, the most common is breast cancer in 66% and lung
cancer in 13.2%. In male population, the lung cancer
predominates with 62.9%, followed in 8.6% by prostatic cancer
[5,6]. At least in part the reason is that these two types of
malignancies are most commonly encountered in clinical
practice. Less often described are metastasis of renal cell
carcinoma, gastrointestinal tumours, lymphomas, leukemias,
thyroid carcinomas, myeloma, hepatocellular carcinoma and
rhabdomyosarcoma (Table 1) [1,2,7–19]. When conﬁrming the
metastasis in the pituitary, there are frequently metastases
present at several other locations, most often in bones.
Our patients had various types of metastases to the
pituitary. The breast cancer is a common one, whereas renal
carcinoma and diffuse large B-cell lymphoma are more rarely
encountered. Especially sellar lymphoma is exceedingly rare.
It includes primary and secondary pituitary lymphoma. Both
may be accompanied by acquired immunodeﬁciency syn-
dromes, whereas the later is a systemic lymphoma involvingTable 1 – The most frequent primary sites of pituitary
metastases.
Primary site Incidence of metastasis
Breast 37.2%
Lung 24.2%
Prostate 8.6%
Renal cell carcinoma 7.5%
Gastrointestinal tumours 6.4%
Thyroid 5.8%
Hepatocellular carcinoma 3%
Lymphomas and leukaemia 0.5%
Rhabdomyosarcoma 0.3%also the pituitary gland. The mean age of the patients is almost
the same, about 60–70 years of age. Since the pituitary gland has
a large reserve capacity, pituitary involvement in lymphoma
also appears to be asymptomatic in most cases until the
advancing stage of the disease. As with metastases, the diabetes
insipidus and visual disturbances are the most common clinical
presentations. Histologically, B-cell non-Hodgkin lymphomas
represent the majority of pituitary lymphomas. Chemotherapy
is the treatment option [20–22].
The incidence of pituitary metastases is independent of
gender. They are more commonly encountered in the sixth
and seventh decades of life [3]. The incidence of metastasis of
breast cancer in the pituitary is rising and these are described
in the 6–29% of patients suffering from breast cancer. There is
no clear explanation and it is assumed that the hormonal
environment of the pituitary gland provides fertile soil for the
implantation of metastatic cells and offers an optimal
environment for their growth [1]. Especially the prolactin
chemotactically affects the breast cancer cells [1,7].
The tumours may metastasize into the pituitary gland and
surrounding area by several ways: (I) hematogenously into the
posterior lobe, (II) from the hypothalamus or infundibulum via
the portal circulation, (III) with progression of metastasis from
extrasellar space and skull base, (IV) thorough meningeal
spreading over suprasellar cistern into the pituitary capsule
[3,7].
Most pituitary metastases are present in the posterior lobe
of the pituitary. Teears et al. have analyzed 88 cases of
metastatic pituitary tumours [6]. In 57%, only the posterior lobe
of the pituitary gland was affected, in 13% the anterior lobe and
in 12% both lobes were affected. The remainder is accounted
for the location of the metastasis in the capsule or the pituitary
stalk. In the posterior part, the metastases were predominant
and in the anterior lobe, the necrosis prevailed. The authors
suggest that the tumour of the posterior lobe of the pituitary
caused an infarction of the anterior lobe, hence the necrotic
tissue on histological examination. This also results in
endocrine abnormalities [6].
It is assumed that most metastases are present in the
posterior pituitary lobe due to its direct arterial blood supply
and therefore higher likelihood of metastasis in comparison to
the anterior lobe, which gets its blood supply from the
hypothalamic-pituitary portal system [1,2,6]. A higher per-
centage of metastases in the posterior lobe can also be a result
of increased contact with the dura that covers the pituitary
gland and produces functional periosteum of the underlying
sella [3,6]. Interestingly, there are no reports about growth of
metastasis into the pituitary from the surrounding cranial
bone [6]. In contrast to Teears et al., some studies found more
frequent involvement of the anterior pituitary, mainly due to
breast cancer metastases [1]. Because of the hormonal
attractiveness, the metastatic breast cancer cells showed a
higher afﬁnity to adenohypophysis. In this research series of
breast cancer metastasis, the anterior pituitary was involved
in 70–82% [1].
The clinical picture of the pituitary metastasis may be
unspeciﬁc. They are frequently silent. Morita et al. observed
that the time from the occurrence of symptoms to the
diagnosis ranges from ten days to three years, with an average
of three months [7]. In our three patients, the time from the
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of the disease ranged from three to four weeks, which conﬁrms
that metastasis to the pituitary gland may be clinically silent
for a long time and become clinically manifest only when they
disturbed the function of the pituitary or in case the tumour
has already affected the surrounding structures. Teears et al.
found that only 7% of metastases to the pituitary were
symptomatic and most of them were discovered during
autopsies [6]. The most common symptoms were diabetes
insipidus in 32.7%, followed by ophthalmoplegia, headache,
vision disturbance, which is reﬂected most often as bitemporal
hemianopsia, impairment of visual acuity and malfunctioning
of the anterior pituitary lobe [2,3,5,7]. As metastases are more
frequent in the posterior pituitary lobe, the majority of
patients usually ﬁrst present with signs of diabetes insipidus,
which may be transient and it occurs as a result of disability of
infundibulum and hypothalamus [3]. The diabetes insipidus is
more frequently described in the pituitary gland metastases
(60%) as in pituitary adenomas (1%). Among the newly
diagnosed patients with diabetes insipidus, 14–20% already
had metastases in bones, which indicates advanced disease
and a long-lasting quiet clinical course [1]. Similar symptoms
were observed also in our patients.
With the pituitary metastases, diabetes insipidus and/or
oculomotor nerve paresis are more common. On the other
hand, for pituitary adenomas, the vision loss and the
malfunction of the anterior lobe are more typical [2,3]. Thus,
the metastases in the pituitary established paresis of eye
movements in 42%, with pituitary adenomas only in 5% [5].
Invasive tumours cause visual deﬁcits due to suprasellar
growth and due to invasion into the cavernous sinus, the
painful ophthalmoplegia may ensue [1]. A lot of dysfunctions
of the pituitary gland may remain blurred due to progression of
the underlying disease. In 56–64% of patients with symptoms
of a tumour in the pituitary gland, this may be the ﬁrst sign of
malignancy. On the other hand, pituitary metastasis are in 20–
30% the ﬁrst sign of primary tumour of an unknown origin [2,7].
Hyperprolactinemia may be caused as a result of pressure on
the pituitary stalk and occurs in 6.3% of cases [3]. The
combination of diabetes insipidus, cranial nerve palsies
(ophthalmoplegia), the rapid course of the disease, headache
and age over 50 years indicate a high probability of pituitary
metastasis [2–4].
For the diagnosis, the MRI of the head is necessary. The
sensitive and speciﬁc criteria, which would distinguish
metastasis from the pituitary adenoma, cannot be exactly
set [5]. In comparison to pituitary adenomas, the pituitary
metastases are characterized by erosion of the cranial bone
without increasing of the sella, bell-shaped sella due to the
expansion through the diaphragm, faster growth and bleeding
[2,5]. The clinical picture is particularly important. However,
the radiological characteristics of metastases on MRI are
numerous: (I) thickening and ampliﬁcation of the pituitary
stalk, (II) loss of the high-intensity signal from the posterior
pituitary lobe, (III) isointensity on T1- and T2-weighted images,
(IV) invasion of the cavernous sinus and suprasellar spreading,
(V) sclerosis in the surroundings of the sella and (VI)
homogeneous appearance of the lesion [1,7]. In endocrinologi-
cal examination, the endocrine dysfunction of the posterior
lobe may be found, as well as anterior lobe dysfunction, whichis reﬂected by lower values of thyroxine, cortisol and
testosterone and a higher value of prolactine. The diagnosis
is deﬁnitely conﬁrmed by pathohistological examination. The
differential diagnosis may include craniopharyngeoma, ger-
minoma, histiocytosis X and pituitary adenoma [7].
The treatment for metastases to the pituitary includes
surgery, stereotactic radiosurgery, radiotherapy with target
irradiation of the whole head, chemotherapy and hormone
replacement therapy. In case of surgical treatment, the
resection through the endoscopic transsphenoidal approach
is performed in most cases. In case of larger lesions, which
spread suprasellary and to the cavernous sinus, it is possible to
use a transcranial approach. A complete resection of the
tumour is usually difﬁcult because of good vascularization and
consequently increased bleeding, local ingrowth into the
surrounding bone and the cavernous sinus and into the
hypothalamus and optic nerves [3]. The surgical resection,
regardless of how radical is performed, does not affect the
survival of these patients [2]. It usually only leads to the
improvement of symptoms such as visual acuity, pain,
ophthalmoplegia, thus enabling a better quality of life when
a good resection is combined with additional radiotherapy
[2,7]. Malfunctions of the anterior pituitary lobe and double
vision due to the cranial nerve palsies are usually permanent.
Improved survival has been demonstrated in local control of
tumour with adjuvant radiotherapy or chemotherapy [1,3,7].
Another reasonable option for treatment of pituitary tumours
besides microsurgery is also stereotactic radiosurgery, which
offers both safe and effective treatment for various intracra-
nial pathologies. Although not curative in malignant tumours,
it has been effective as a palliative approach for most patients,
improving their survival and the quality of life. On the other
hand, radiosurgery in benign tumours leads to the control of
tumour size in the majority of patients [23,24].
The indications for surgical treatment are the mass effect of
the tumour with deterioration of vision, pain and the need to
obtain histological sample [3,7]. Morita et al. reported a study
of 36 patients with pituitary metastases. They operated on 21
patients. Surgery was performed in 16 patients over a
transsphenoidal approach and in ﬁve patients a transcranial
route was used because the tumour was larger and extended
suprasellary and into the cavernous sinus. Described among
the complications of transsphenoid intervention were cere-
brospinal ﬂuid leak, carcinomatous meningitis and deteriora-
tion of endocrine function [7].
The surgical treatment is usually followed by adjuvant
radiotherapy, with the possibility of local irradiation or
irradiation of the whole head. Chemotherapy is also widely
used, however; its effect in the studies so far is not clearly
deﬁned [1]. A palliative therapy is recommended by some
authors [7].
The prognosis of the disease depends on the type of the
tumour or the degree of malignancy of the primary tumour.
The metastases to the pituitary gland are usually discovered in
the terminal phase of the disease, when disseminated
metastases are usually present. Due to concomitant symp-
toms of malignancy, such as weakness, vomiting and weight
loss, the symptoms of pituitary metastases are often obscured
[3,6,7]. Micrometastases may also be present and they are not
often evident on diagnostic imaging. In these cases, the
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median overall survival is from six to 22 months and only 10%
of patients survive more than one year [1,4,7]. Death usually
occurs due to the advancement of metastases, other brain
metastases, pulmonary embolism, mass effects of the metas-
tasis in the pituitary gland, meningeal carcinomatosis and
local growth of the primary tumour [7].
4. Conclusions
Although the metastases to the pituitary are rare, their
incidence is rising with the advancement of medical diag-
nostics and the prolongation of the survival of the cancer
patients. In case of diabetes insipidus, elderly patient, rapid
progression of relevant symptoms and lesions in the area of
the pituitary gland visible on MRI of the head, it is necessary to
think about pituitary metastasis. Although a successful
operative and adjuvant therapy may help to improve the
symptoms and quality of life, the long-term survival of these
patients depends on the success in the treatment of the
underlying disease.
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